Across the Midwest, a veteran looking for help with stubborn depression runs into a lot of confident advice. Some comes from buddies, some from online groups, some from ads that follow you around the internet after a single search. A good share of it is wrong, and some of it is wrong in ways that could steer you toward less safe care or away from options you have earned.
Here are six common beliefs about where depression treatment happens, clinic, home, or a mix, checked against the medical facts and against a June poll of 443 Midwest adults, drawn from ten states and funded by our publisher. The survey sampled the general public, not veterans as a group. Its figures describe everyone who answered, taken from the final validated data.
Myth 1: A veteran needs some special channel to get this care
Not true. Veterans see the same primary care doctors and psychiatrists as everyone else, using TRICARE, Medicare, Medicaid, or private insurance. There is no separate veterans-only door to newer depression treatments, and waiting for one can cost months.
Most people start in an ordinary doctor's office. When our survey asked for someone's first stop when exploring a newer depression treatment, the family doctor won 56 percent of the vote, with psychiatric specialists taking 23 percent. Veterans and service members were only about 2 percent of respondents, and adding first responders brings that group to just 29 people, so these are general-public habits, but the door they describe is open to veterans too.
Myth 2: Everybody does mental health by video now
Not quite. Telehealth is a real and useful tool, especially across the rural stretches of Nebraska, Kansas, and Iowa. Yet on the survey's delivery question about ketamine or esketamine, doing it all from home by telehealth attracted only 22 percent.
The in-person clinic led at 44 percent. The hybrid route, clinic first with home follow-up, edged past it at 23 percent. Merge the clinic and hybrid groups and 67 percent wanted a clinic somewhere in the plan. Eleven percent had no preference.
For a veteran in a small town, that says something practical. Telehealth is worth asking about for check-ins and therapy, but a plan that keeps a clinic in the picture is what most people would choose for themselves, and it is where the one approved option in this family lives.
Myth 3: At-home ketamine is just the clinic version by mail
False, and the difference matters. The ketamine-family drug approved for depression is esketamine, sold as Spravato. It is approved for treatment-resistant depression, and its label restricts it to certified healthcare settings, where staff observe the patient after each dose. The patient does not take it home and does not drive afterward.
The ketamine that telehealth outfits ship to homes is a different product, generic ketamine used off-label, usually as a lozenge or tablet. It is taken without a clinician present. Oversight ranges from careful to minimal. It is not a mail-order version of Spravato. Brain Recovery Centers lays out what an in-clinic Spravato session involves for anyone comparing the two.
Myth 4: Ketamine is approved for PTSD
Not true. Esketamine's label names two uses: treatment-resistant depression, and, taken alongside an oral antidepressant, adult major depression marked by acute suicidal ideas or actions. That list leaves out PTSD. Some research is ongoing, and you may hear about it, but "being studied" is not the same as "approved."
Plenty of veterans live with both conditions at once, and sorting out which is driving which is a job for a clinician. PTSD has its own established treatments, including specific forms of trauma-focused therapy, and those are worth asking about in their own right.
Myth 5: Coverage is somebody else's job to sort out
Not in practice. Whoever pays, the patient usually ends up making the calls. On TRICARE, ask whether you need a referral or prior authorization and whether the clinic is TRICARE-authorized. With Medicare or a private plan, find out whether esketamine is on the formulary and which certified sites the plan counts as in network. And tell every provider about all of your medications, so nobody is prescribing blind.
Coverage will be on your mind, and it is on almost everyone's. In our survey, 85 percent of respondents weighing a provider slotted "covered by insurance" into their top two. Asked to choose between covered care with extra steps and cash-pay care with fewer, respondents took the covered path by more than two to one.
Myth 6: A convincing post from a fellow veteran is a good reason to try something
It can be a good reason to ask. It is not a good reason to decide. Stories from other veterans can break the silence around depression, and that is valuable. But in our survey, only 4 percent said a veteran or responder they follow on social media would persuade them. Friends and family moved 18 percent. A person's own doctor moved 74 percent.
That ranking reflects something sensible. The person who has your chart, knows your medications, and understands your heart, blood pressure, and substance history is the one who can say whether a treatment is safe for you.
What is actually true
- Veterans can walk through the same doors as everyone else, starting with a primary doctor.
- Most people want a clinic involved, and the lone ketamine-family option with FDA approval demands one.
- At-home ketamine is off-label and less supervised. It is not Spravato.
- Esketamine is not approved for PTSD.
- Your own clinician is the right person to weigh any of this.
A final context point: 72 percent of respondents reported that depression, anxiety, or PTSD had failed to lift on standard medication for them or someone close. If that describes you, the question of what comes next is fair to ask.
Treat this as information rather than medical advice; no treatment is sure to help.
Thoughts of ending your life deserve a call today, not someday. Dial or text 988, and a veteran can press 1; a family member or friend can make the call for you, and the line is staffed around the clock.
Methodology
Paid for and commissioned by the publisher, this survey was hosted by Pollfish's consumer panel with a June 23, 2026 closing date. It gathered n=443 responses, every respondent between 18 and 64, across Indiana, Ohio, Illinois, Wisconsin, Minnesota, Iowa, Missouri, Nebraska, Kansas, and Oklahoma. Veterans were too few in the sample for their own figures. The results are final, drawn from validated data.